Keywords: GLP-1, obesity, overweight, fractures, bone, pharmacotherapy Introduction GLP-1 RAs were first identified in the 1980s and received FDA approval in 2005 as anti-hyperglycemic agents for the treatment of diabetes (1)
For a Stamford patient, that may mean weight loss, appetite control, fatigue, joint pain, menopause symptoms, low testosterone symptoms, thyroid concerns, inflammation, poor recovery, or a desire to age with more strength and energy
In addition to helping with occasional digestive issues, like gas or bloating, the strain has also been shown to be effective for preventing or managing traveler's diarrhea and antibiotic-associated diarrhea
Using Zepbound, which can reduce appetite, might make it challenging to eat enough